21 results
PRE 14A
LRMR
Larimar Therapeutics Inc
12 Apr 24
Preliminary proxy
6:06am
that the Board is capable of effectively overseeing the execution of our business and meeting the Company’s evolving needs, with diversity reflecting gender, age … , race, ethnicity, sexual orientation, gender identity, social and economic background, professional experience and perspectives. The Nominating
8-K
EX-10.1
LRMR
Larimar Therapeutics Inc
21 May 21
Entry into a Material Definitive Agreement
9:30am
and plural and pronouns stated in either the masculine, the feminine or neuter gender shall include the masculine, feminine and neuter, (d) the use
8-K
EX-10.1
ifw3pm264optltb
2 Jun 20
Chondrial Therapeutics and Zafgen Complete Merger and Begin Operating as Larimar Therapeutics
7:49am
8-K
EX-2.1
yu9hxchd
18 Dec 19
Zafgen and Chondrial Therapeutics Announce Definitive Merger Agreement
8:13am
DEFA14A
EX-2.1
ezk3r
18 Dec 19
Additional proxy soliciting materials
8:11am
8-K
EX-10.2
8im7nou4xyzfvd
30 May 18
Zafgen, Inc. Expands Executive Leadership Team with Appointment of
5:17pm
8-K
EX-10.3
a2ystj e0763
12 Oct 17
Zafgen Appoints Jeffrey Hatfield as Chief Executive Officer; Thomas Hughes, Ph.D. to Continue as President, Appointed Chief Scientific Officer
12:00am
424B4
fw12ut7
23 Jan 15
Prospectus supplement with pricing info
12:00am
424B4
oishml
19 Jun 14
Prospectus supplement with pricing info
12:00am